These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 10601550)
1. Differentiation of human breast carcinoma cells by a novel vitamin D analog: 1alpha-hydroxyvitamin D5. Mehta RR; Bratescu L; Graves JM; Green A; Mehta RG Int J Oncol; 2000 Jan; 16(1):65-73. PubMed ID: 10601550 [TBL] [Abstract][Full Text] [Related]
2. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5. Mehta RG; Moriarty RM; Mehta RR; Penmasta R; Lazzaro G; Constantinou A; Guo L J Natl Cancer Inst; 1997 Feb; 89(3):212-8. PubMed ID: 9017001 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and mechanism of action of 1alpha-hydroxy-24-ethyl-cholecalciferol (1alpha[OH]D5) in breast cancer prevention and therapy. Hussain EA; Mehta RR; Ray R; Das Gupta TK; Mehta RG Recent Results Cancer Res; 2003; 164():393-411. PubMed ID: 12899538 [TBL] [Abstract][Full Text] [Related]
4. Effect of vitamin D analog (1alpha hydroxy D5) immunoconjugated to Her-2 antibody on breast cancer. Punj V; Graves JM; Mehta RR Int J Cancer; 2004 Mar; 108(6):922-9. PubMed ID: 14712498 [TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of mammary carcinogenesis by 1alpha-hydroxyvitamin D5, a synthetic analog of Vitamin D. Mehta RG; Hussain EA; Mehta RR; Das Gupta TK Mutat Res; 2003; 523-524():253-64. PubMed ID: 12628523 [TBL] [Abstract][Full Text] [Related]
6. MART-10, a less calcemic vitamin D analog, is more potent than 1α,25-dihydroxyvitamin D3 in inhibiting the metastatic potential of MCF-7 breast cancer cells in vitro. Chiang KC; Chen SC; Yeh CN; Pang JH; Shen SC; Hsu JT; Liu YY; Chen LW; Kuo SF; Takano M; Kittaka A; Sun CC; Juang HH; Chen TC J Steroid Biochem Mol Biol; 2014 Jan; 139():54-60. PubMed ID: 24125734 [TBL] [Abstract][Full Text] [Related]
7. Growth inhibition of carcinogen-transformed MCF-12F breast epithelial cells and hormone-sensitive BT-474 breast cancer cells by 1alpha-hydroxyvitamin D5. Hussain-Hakimjee EA; Peng X; Mehta RR; Mehta RG Carcinogenesis; 2006 Mar; 27(3):551-9. PubMed ID: 16195238 [TBL] [Abstract][Full Text] [Related]
8. Induction of differentiation by 1alpha-hydroxyvitamin D(5) in T47D human breast cancer cells and its interaction with vitamin D receptors. Lazzaro G; Agadir A; Qing W; Poria M; Mehta RR; Moriarty RM; Das Gupta TK; Zhang XK; Mehta RG Eur J Cancer; 2000 Apr; 36(6):780-6. PubMed ID: 10762752 [TBL] [Abstract][Full Text] [Related]
9. Chemoprevention of chemically-induced mammary and colon carcinogenesis by 1alpha-hydroxyvitamin D5. Murillo G; Mehta RG J Steroid Biochem Mol Biol; 2005 Oct; 97(1-2):129-36. PubMed ID: 16051482 [TBL] [Abstract][Full Text] [Related]
10. C15-functionalized 16-ene-1α,25-dihydroxyvitamin D3 is a new vitamin D analog with unique biological properties. Kumagai G; Takano M; Shindo K; Sawada D; Saito N; Saito H; Kakuda S; Takagi K; Takimoto-Kamimura M; Takenouchi K; Chen TC; Kittaka A Anticancer Res; 2012 Jan; 32(1):311-7. PubMed ID: 22213321 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological activities of the two C(23) epimers of 1alpha,23,25-trihydroxy-24-oxo-19-nor-vitamin D(3): novel analogs of 1alpha,23(S),25-trihydroxy-24-oxo-vitamin D(3), a natural metabolite of 1alpha,25-dihydroxyvitamin D(3). Lee NE; Williard PG; Brown AJ; Campbell MJ; Koeffler HP; Peleg S; Rao DS; Reddy GS Steroids; 2000 May; 65(5):252-65. PubMed ID: 10751637 [TBL] [Abstract][Full Text] [Related]
13. The effects of 1alpha,24(S)-dihydroxyvitamin D(2) analog on cancer cell proliferation and cytokine expression. Shany S; Levy Y; Lahav-Cohen M Steroids; 2001; 66(3-5):319-25. PubMed ID: 11179740 [TBL] [Abstract][Full Text] [Related]
14. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines. Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1alpha-hydroxyvitamin D5. Peng X; Jhaveri P; Hussain-Hakimjee EA; Mehta RG Carcinogenesis; 2007 May; 28(5):1000-7. PubMed ID: 17130524 [TBL] [Abstract][Full Text] [Related]
16. Differentiating and antitumor activities of 1 alpha,25-dihydroxyvitamin D3 in vitro and 1 alpha-hydroxyvitamin D3 in vivo on human osteosarcoma. Tsuchiya H; Morishita H; Tomita K; Ueda Y; Tanaka M J Orthop Res; 1993 Jan; 11(1):122-30. PubMed ID: 8423514 [TBL] [Abstract][Full Text] [Related]
17. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089. VanWeelden K; Flanagan L; Binderup L; Tenniswood M; Welsh J Endocrinology; 1998 Apr; 139(4):2102-10. PubMed ID: 9528999 [TBL] [Abstract][Full Text] [Related]
18. Vitamin D analogs, 20-Epi-22-oxa-24a,26a,27a,-trihomo-1alpha,25(OH)2-vitamin D3, 1,24(OH)2-22-ene-24-cyclopropyl-vitamin D3 and 1alpha,25(OH)2-lumisterol3 prime NB4 leukemia cells for monocytic differentiation via nongenomic signaling pathways, involving calcium and calpain. Berry DM; Meckling-Gill KA Endocrinology; 1999 Oct; 140(10):4779-88. PubMed ID: 10499538 [TBL] [Abstract][Full Text] [Related]
19. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells. Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668 [TBL] [Abstract][Full Text] [Related]
20. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Abe J; Nakano T; Nishii Y; Matsumoto T; Ogata E; Ikeda K Endocrinology; 1991 Aug; 129(2):832-7. PubMed ID: 1855478 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]